Xu Yuan 4

What Happened

• Xu Yuan, a member of the Fate Therapeutics (FATE) board of directors, was granted a derivative award (options) for 87,900 shares on June 12, 2026. The Form 4 lists the acquisition price as $0.00, indicating this was an equity grant rather than a cash purchase or open‑market trade.

Key Details

• Transaction date: June 12, 2026; filing date: June 15, 2026 (reported on Form 4, appears timely).
• Transaction type/code: A (award/grant of derivative securities); reported dollar amount: $0.00.
• Shares involved: 87,900 underlying shares subject to the option grant.
• Vesting: The options vest and become exercisable on the earlier of (i) June 12, 2027 or (ii) the Issuer's 2027 Annual Meeting of Stockholders, subject to Xu Yuan’s continued board service (per filing footnote).
• Shares owned after transaction: Not specified in the filing.
• Notes: Grant made under the company’s Amended and Restated Non‑Employee Director Compensation Policy (annual director equity grants).

Context

• This was a standard non‑employee director equity grant, common as part of board compensation; it is a derivative award (options) that must vest and typically be exercised later to realize cash value. The Form 4 shows $0.00 for the acquisition price because it records the grant rather than an open‑market purchase; the option’s exercise/strike price is not disclosed in this filing. Such routine director grants are compensation/retention measures and should not be interpreted alone as a signal to buy or sell stock.